Sunnnary. Diabetic patients with elevated urinary albumin excretion rate (incipient or clinical nephropathy)also have an increased transcapillary escape rate of albumin. This study was designed to clarify whether this is caused by a general vascular dysfunction or by elevated systemic blood pressure. The systemic blood pressure and the transcapillary escape rate of albumin were measured in the following groups after 4weeks without antihypertensive treatment: Group ieleven healthy control subjects. Group 2 -ten Type 1 (insulin-dependent) diabetic patients with incipient nephropathy (urinary albumin excretion rate: 30-300 mg/24 h) and normal blood pressure. Group 3 -eleven non-diabetic patients with essential hypertension. Group 4 -nine Type 1 diabetic patients with hypertension but normal urinary albumin excretion ( < 30 mg/24 h). Group 5 -eleven Type 1 diabetic patients with nephropathy (urinary albumin excretion rate > 300 mg/24 h) and hypertension. Systolic and diastolic blood pressure were similar in the three hypertensive groups: group 3, 148 + 8/95 + 6; group 4, 150 + 12/94 + 8 and group 5; 152+12/92 +7 mmHg, but significantly elevated (p < 0.001) compared to control group 1,117 + 12/74 + 9 and group 2, 128 + 7/82 + 4 mm Hg. The transcapillary escape rate of albumin was similar in the control subjects (5.2+2.7%) and the subjects in the normoalbuminuric groups 3 and 4 (6.2 + 1.9 and 5.1 _+ 1.4%, respectively) and significantly lower (p < 0.001) than in patients with elevated urinary albumin excretion without or with hypertension group 2, 10.1 + 2.8 and group 5, 11.4 + 5.7 %. The increased trariscapillary escape rate of albumin in patients with elevated urinary albumin excretion is unrelated to moderate systemic hypertension and may therefore be caused by alterations in the properties of the capillary walls.
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The role of hypertension in the development of diabetic nephropathy is still debated. The question is whether hypertension is an initiating factor of diabetic nephropathy causing albuminuria or whether hypertension is only secondary to other factors which lead to the increased transglomerular albumin sieving of nephropathy. We have suggested that the cause of the elevated transglomerular passage of albumin is genetically determined alterations in the composition of the extracellular matrix [1] . These alterations may also be present in extra-renal capillaries and thus, albuminuria reflects more generalized vascular damage. This hypothesis was based on studies of the transcapillary escape rate of albumin (TgRalb). TERam is a measure of the unidirectional microvascular flux of plasma albumin in renal and extra-renal tissues [2] . It has been interpreted as a marker of general vascular dysfunction [3] . In our study of long-term diabetic patients with no signs of late diabetic complications (i. e. normal urinary albumin excretion) we observed a normal TERalb [4] . In contrast, an elevated TERalb was seen in patients with normal blood pressure but slightly elevated urinary albumin excretion (UAE) rate (incipient nephropathy). The TERalb in these normotensive patients was elevated to the same degree as in patients with clinical nephropathy.
The present study was designed to further clarify the roles of vascular dysfunction and elevated systemic blood pressure on the TERalb iI1 Type 1 (insulin-dependent) 
Subjects and methods

Patients
Five groups of subjects were studied. The subjects were aged 18-50 years ( . UAE measured annually in the clinic had never been above 30 rag/24 h either before or after antihypertensive treatment (if any) was initiated. Fulfilling these criteria, we defined these patients as having essential hypertension coexistent with Type 1 diabetes as previously described [5] . Group 5: eleven Type1 diabetic patients with clinical nephropathy, i.e. UAE > 300 rag/24 h in at least two out of three urine collections and other renal diseases excluded. All had hypertension, as defined for groups 3 and 4, and serum creatinine was normal ( < 100 gmol/1). In all the patients with Type i diabetes (those in groups 2, 4 and 5) the onset of diabetes had been prior to the age of 31 years, and these patients were randomly selected from patients fulfilling the criteria for each group who were attending Steno Diabetes Center. The patients in group 3 were attending the Hypertension Clinic at Bispebjerg Hospital, Copenhagen and were also randomly selected. In order to avoid development of severe hypertension during 4 weeks without antihypertensive treatment, the patients in the three hypertensive groups (groups 3, 4 and 5) were selected from those patients whose blood pressure was relatively well-controlled ( _< 170/100) by taking two different antihypertensive drugs or less.
Informed consent for participation was obtained, and the study was approved by the Regional Scientific Ethics Committee.
Study design and methods
All patients were studied in our laboratory after having discontinued antihypertensive treatment for at least 4 weeks (if on treatment). Blood pressure was measured every week. If systolic pressure exeeded 200 mmHg and/or diastolic pressure exeeded 110 mmHg or in case of any discomfort of the patients (n = I from group 4 and n = 5 from group 5), the patients were withdrawn from the study and antihypertensive treatment instituted again. Numbers of patients using the following antihypertensive drugs: none/diuretics/betablockers/angiotensin converting enzymes/calcium channel blockers prior to the study were, for group 3: 7/3/0/2/1, for group 4: 0/5/1/2/1, and for group 5: 0/5/2/4/3. In the last week before the study the patients in groups 2-5 collected two 24-h urine samples for UAE rate determination. All subjects were studied after an overnight fast, the diabetic patients omitting their morning insulin. A cannula was inserted into the antecubital veitl in each arm and blood samples were collected after 30-min rest in the supine position. Blood pressure was measured twice with a random zero sphygmomanometer (Hawksley, West Sussex, UK) and expressed as the mean value. The TERatb K. NCrgaard et al.: Albumin leakage and hypertension is the fraction of the intravascular albumin mass leaving the vascular bed per hour (%/h). TERalb was determined after an intravenous injection of 40 kBq lz~I-labelled human serum albumin. The radioactivity of plasma sampled at 10, 20, 30, 40, 50, 60 min after the injection was used for calculation. TER,~b is the rate constant of the practically monoexponential decrease in plasma radioactivity over the first 60 rain after the injection of the tracer, and calculated by the least squares method [6] . The haematocrit was measured in each sample and the plasma radioactivity was expressed according to the small change in plasma volume during the sampling period. The TER~Ib measurement was accepted only if the correlation coefficient between the time points for blood sampling and the corresponding values of In (plasma radioactivity) exceeded 0.85. Because of this criteria three patients were excluded from the study. The degree of diabetic retinopathy was scored after direct ophthalmoscopy through dilated pupils as none, background retinopathy, proliferative retinopathy or blindness.
Laboratory measurements
Haemoglobin AI0 was measured by HPLC (Bio Rad DIAMAT, Richmond, Calif., USA) (normal range 4.3-6.2 %). Blood glucose was measured by means of Hypocount B (Hypoguard LD, Woodbridge, Suffolk, UK). Serum creatinine was measured by a reaction rate kinetic principle eliminating pseudo-creatinines [7] . Urinary albumin concentration was determined using an ELISA-assay and expressed as median of three 24-h collections [8] .
Statistical analysis
Results are given as mean_+ SD for the normally distributed data. UAE rates are given as median and range. Significant group differences were detected by Duncan's multiple range test. The test was performed for UAE after logarithmic transformation of the data. Linear regression analysis was used to detect any correlations between TER~Ib and blood pressure. Comparison of retinopathy in the groups was performed using chi-square test. A p -value (two-tailed) below 0.05 was considered significant.
Results
Clinical data are given in Table 2 . The five groups were matched for age and gender distribution. Diabetes duration in the three diabetic groups was similar. The diabetic groups were treated with a comparable daily dose of insulin. The glycaemic control (HbAlc) differed between the three diabetic groups. Group 2:9.2 + 1.0 % was significantly higher than group4: 7.8+0.8% and group5: 8.2 + 1.1% (p < 0.001). The actual blood glucose on the study day was similar in all the diabetic groups. The degree of retinopathy in the diabetic groups was scored as none/background retinopathy/proliferative retinopathy/blindness. Patients with coexistence of essential hypertension had significantly less retinal changes than the albuminuric groups; group 4:6/3/0/0 vs group 2:2/5/1/2 (p < 0.05) and vs group 5:0/3/6/2 (p < 0.05). Both systolic and diastolic blood pressure were comparable in the three hypertensive groups (group 3: systolic 148 + 8, diastolic 95 + 6; group 4: systolic 150 + 12, diastolic 94 + 8; and group 5: systolic 152 + 12 mmHg, diastolic 92 + 7 mmHg) and elevated as compared to the control subjects (117 + 12/74 + 9 mmHg, p < 0.001) and the normotensive patients with microalbuminuria (128 +7/82 +_ 4,p < 0.001) (Fig. 1) . Normotensive diabetic patients with incipient nephropathy had slightly elevated blood pressure compared to the control subjects. A statistically significant group difference was documented for TERalb (p <0.001). The TER,ib was similar in control subjects (group 1: 5.2 + 2.7 %), non-diabetic subjects with essential hypertension (group 3:6.2 + 1.9 %) and Type i diabetic patients with essential hypertension (group 4:5.1 + 1.4 %), and significant lower than in diabetic patients with clinical nephropathy (group 5:11.4 + 5.7 %) and microalbuminuria (group 2:10.1 + 2.8 %) (Fig. 2) . No significant correlation was found between either systolic or diastolic blood pressure and TER,~b in any of the groups. Neither was there any significant correlation between blood pressure and TER~lb when testing the albuminuric diabetic patients (groups 2 and 5, n = 21).
Discussion
This study has shown that TERalb is elevated in Type 1 diabetic patients with elevated UAE regardless of whether the blood pressure was elevated, and that TERalb is normal in moderately hypertensive diabetic patients, with a normal UAE, as well as in non-diabetic patients with essential hypertension.
The elevated TERaib in albuminuric patients does not seem to be explained by increased urinary albumin loss. Assuming a plasma volume of 3000 ml and a plasma concentration of albumin 40 g/l, an increase in TERalb from 5 % to 10%, as reported in the present study, represents an increased albumin leakage of 6 g/h. None of the albuminuric diabetic patients had a UAE higher than 160 rag/h, and TERolb was increased to the same level in patients with incipient and clinical nephropathy despite a 10-fold difference in UAE between the two groups.
In the present study, the two groups of hypertensive diabetic patients (group 4 and group 5) had the same moderate degree of hypertension, the same diabetes duration and similar blood glucose values during the measurement of TERalb but the TER~b was elevated only in the presence of an excess loss of albumin in the urine (group 5). This suggests that generalised endothelial cell dysfunction is responsible for the increased TERalb in this group of patients, as also discussed below. Generalised endothelial dysfunction is evident in diabetic patients with nephropathy [3, 9, 10] . A previous study by our group [11] also gave support to the concept that the level of the TER~b should be related to generalized vascular dysfunc- tion. In this study, the TERalb was lowered in diabetic patients with early nephropathy receiving dietary cod-liver oil supply for 8 weeks. The change in TERalb was not correlated to the small reduction seen in blood pressure. Furthermore, in a previous study in normotensive albuminuric patients, the TER~b remained stable in spite of a reduction of 8mmHg systolic and 5 mmHg diastolic blood pressure [12] . In previous studies different factors were found to be of importance for the level of the TER~b in Type i diabetic patients. Poor glycaemic control has been demonstrated to increase vascular permeability in short-term diabetic patients [13] . In a study comprising some Type i but mostly Type 2 (non-insulin-dependent) diabetic patients without complications, O'Hare and co-workers [14] were able to reduce TER~Ib from 8.8 % to 6.3 % by improving glycaemic control for 3 weeks. However, in patients with microalbuminuria, the glycaemic control did not seem to contribute to the level of TERa~b [4] . In the present study we found that group 4 of diabetic patients with essential hypertension and normal TER,~u had significantly lower HbAlc than microalbuminuric normotensive patients. The actual blood glucose was however similar between the groups and HbAlc was similar between groups 4 and 5. Furthermore, there was no significant correlation between HbAlc and TER~ib. Therefore, the observed differences in TERalb are not likely to be explained by differences in glycaemic control.
It is well known that TERa~b is elevated in essential hypertensive patients, with very high blood pressure levels in whom a correlation between TER~b and blood pressure has been described [6] . We found a normal TERalb in non-diabetic patients with essential hypertension possibly because we studied only patients with moderate hypertension. Thus, in a previous study from Parring and Gyntelberg [6] the TER~b was normal up to a level of diastolic pressure of 120 mmHg and none of the hypertensive patients in our study exceeded that level. It is relevant to include only patients with low range hypertension when studying the mechanisms initiating diabetic nephropathy, because the blood pressure in patients with incipient nephropathy is only slightly elevated [15, 16] . O'Hare et al. [14] stated that hypertension independently increases TERalb in diabetic patients without complications. In their study the normotensive and hypertensive patients were not matched as in the present study, specifically with respect to the type of diabetes, age and weight. Their results are in contrast to those presented here where we found that moderate hypertension, in Type 1 diabetic patients free of severe long-term complications, does not influence the TERalb. The TER~b was elevated only in the presence of elevated albuminuria and unrelated to the presence of hypertension.
Autoregulation of blood flow is the ability to maintain almost constant blood flow in the microcirculation during changes in the arterial blood pressure. Theoretically, an impaired autoregulation could affect the level of TER,lb. We did not evaluate the autoregulatory capacity of the patients: It is, however, unlikely that the observed association of an elevated TERalb and an increased UAE could be explained by loss of autoregulatory capacity, as quite dramatic differences in autoregulation should be present to explain an increase in TERalb in patients with a mean blood pressure an average of 16 mmHg below the level of patients with normal TER~lb (group 2 vs group 4).
In conclusion, increased TER~b in patients with elevated UAE is unrelated to moderate systemic hypertension and seems rather to be caused by alterations in the properties of the capillary walls.
